Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy.

In the ELM-2 study (NCT03888105) of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) (n = 141), odronextamab 160 mg weekly (after step-up dosing) significantly improved Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Lymphoma Subscale (LymS, least squares mean [95% confidence interval], 3.02 [1.76, 4.27]), FACT-General (FACT-G, 2.85 [0.81, 4.90]), Trial Outcome Index (TOI, 4.56 [2.18, 6.94]), and Total Score (5.64 [2.64, 8.64]); as well as European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status/quality of life scale (GHS/QoL, 4.04 [1.23, 6.84]) and EQ-5D-3L visual analog scale (VAS, 3.59 [0.79, 6.39]) for overall health status. The least squares mean improvement in FACT LymS was clinically meaningful and patients were more likely to report clinically meaningful improvement or maintenance than clinically meaningful worsening overall for every scale. These improvements in patient-reported outcomes support the feasibility of odronextamab monotherapy regimen as a potential treatment option in r/r DLBCL.